Cleo Diagnostics Ltd (ASX:COV)

Australia · Delayed Price · Currency is AUD

0.4750

0.00 (0.00%)

At close: Jun 26, 2026

28.38% (1Y)

Market Cap	65.01M +44.5%
Revenue (ttm)	2.56M +1,115.5%
Net Income	-4.03M
EPS	-0.03
Shares Out	136.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117,056
Open	0.4850
Previous Close	0.4750
Day's Range	0.4650 - 0.4850
52-Week Range	0.3350 - 0.9000
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Cleo Diagnostics

Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia. [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2021

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol COV

Full Company Profile

Financial Performance

In fiscal year 2025, Cleo Diagnostics's revenue was 845,172, an increase of 300.91% compared to the previous year's 210,812. Losses were -4.00 million, 6.38% more than in 2024.

Financial Statements